1 results
in Articles
-
Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol.
ArticleOBJECTIVETo review the current pharmacology, pharmacokinetics/pharmacodynamics, safety, and efficacy of inclisiran in lowering lipid levels.DATA SOURCESA PubMed (from December 1, 2014 to April 15, 2022) and ClinicalTrials.gov search was conducted us…